Key result
Female sex was an independent predictor of functional class improvement in HFrEF patients treated with sacubitril/valsartan (OR 2.33; 95% CI 1.24-4.38; p=0.04).
Why the study?
Women are underrepresented in sacubitril/valsartan clinical trials, leaving sex-specific differences in efficacy, tolerability, and safety unclear in real-world HFrEF patients.
Does female sex influence the efficacy, tolerability, and safety of sacubitril/valsartan in patients with HFrEF?
Population
427 real-world HFrEF patients starting sacubitril/valsartan across 10 centers
Comparison
Women vs men treated with sacubitril/valsartan
Design
Multicenter prospective registry
Follow-up
Mean 7.0 ± 0.1 months
Authors
Loading...
May indicate greater functional response to sacubitril/valsartan in women with HFrEF; hypothesis-generating and requires RCT confirmation.
Observational (n=427)
Yes
Does female sex influence the efficacy, tolerability, and safety of sacubitril/valsartan in patients with HFrEF?
Odds Ratio: 2.33 (95% CI 1.24–4.38)
p-value: p=0.04
In real-world HFrEF patients, sacubitril/valsartan shows similar tolerability between sexes, but women may experience more frequent functional class improvement.
Vicent et al. (2019) conducted an observational in heart failure with reduced ejection fraction (HFrEF) (n=427). Female sex vs. Male sex was evaluated on functional class improvement (OR 2.33, 95% CI 1.24-4.38, p=0.04). Female sex was an independent predictor of functional class improvement in HFrEF patients treated with sacubitril/valsartan (OR 2.33; 95% CI 1.24-4.38; p=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: